Jiangsu Nanfang Medical Net Assets
Jiangsu Nanfang Medical net assets. Based on the latest financial reports, Jiangsu Nanfang Medical (603880) has net assets worth CN¥163.51 Million CNY (≈ $23.93 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥874.85 Million ≈ $128.02 Million USD) and total liabilities (CN¥711.34 Million ≈ $104.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Jiangsu Nanfang Medical to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥163.51 Million |
| % of Total Assets | 18.69% |
| Annual Growth Rate | 3.13% |
| 5-Year Change | -72.34% |
| 10-Year Change | -29.42% |
| Growth Volatility | 36.74 |
Net Assets of Jiangsu Nanfang Medical (2012–2025)
Net assets of Jiangsu Nanfang Medical from 2012 to 2025. This chart illustrates how Jiangsu Nanfang Medical's net assets have evolved over time, based on quarterly financial data. See how leveraged is Jiangsu Nanfang Medical's balance sheet to measure how much of total assets are equity-financed.
Annual Net Assets for Jiangsu Nanfang Medical (2012–2025)
The table below shows the annual net assets of Jiangsu Nanfang Medical from 2012 to 2025. For live market cap and overall valuation, see Jiangsu Nanfang Medical (603880) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥181.17 Million ≈ $26.51 Million |
-36.30% |
| 2024-12-31 | CN¥284.41 Million ≈ $41.62 Million |
-40.03% |
| 2023-12-31 | CN¥474.22 Million ≈ $69.39 Million |
-23.70% |
| 2022-12-31 | CN¥621.48 Million ≈ $90.94 Million |
-5.10% |
| 2021-12-31 | CN¥654.90 Million ≈ $95.83 Million |
-6.55% |
| 2020-12-31 | CN¥700.80 Million ≈ $102.55 Million |
+23.48% |
| 2019-12-31 | CN¥567.52 Million ≈ $83.05 Million |
+1.34% |
| 2018-12-31 | CN¥560.04 Million ≈ $81.95 Million |
+4.18% |
| 2017-12-31 | CN¥537.57 Million ≈ $78.66 Million |
+109.43% |
| 2016-12-31 | CN¥256.69 Million ≈ $37.56 Million |
+15.36% |
| 2015-12-31 | CN¥222.51 Million ≈ $32.56 Million |
+5.50% |
| 2014-12-31 | CN¥210.90 Million ≈ $30.86 Million |
+25.11% |
| 2013-12-31 | CN¥168.57 Million ≈ $24.67 Million |
+38.88% |
| 2012-12-31 | CN¥121.38 Million ≈ $17.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Jiangsu Nanfang Medical's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1808.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Jiangsu Nanfang Medical Net Assets Breakdown (December 2025)
Jiangsu Nanfang Medical net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥437.13 Million | 246.70% |
| Total Equity | CN¥177.19 Million | 100.00% |
Jiangsu Nanfang Medical Competitors by Market Cap
The table below lists competitors of Jiangsu Nanfang Medical ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
John Marshall Bancorp Inc
NASDAQ:JMSB
|
$327.40 Million |
|
Orchestra BioMed Holdings Inc.
NASDAQ:OBIO
|
$327.57 Million |
|
Taiwan Paiho Ltd
TW:9938
|
$327.62 Million |
|
Symtek Automation Asia Co Ltd
TW:6438
|
$327.63 Million |
|
Aurora Cannabis Inc
TO:ACB
|
$327.31 Million |
|
ADTRAN Inc
NASDAQ:ADTN
|
$327.23 Million |
|
Peijia Medical Limited
F:4WO
|
$327.18 Million |
|
eMudhra Limited
NSE:EMUDHRA
|
$327.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Jiangsu Nanfang Medical's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 279,286,644 to 177,190,384, a change of -102,096,260 (-36.6%).
- Net loss of 101,710,551 reduced equity.
- Dividend payments of 25,903,210 reduced retained earnings.
- Other comprehensive income decreased equity by 42,229,076.
- Other factors increased equity by 67,746,577.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-101.71 Million | -57.4% |
| Dividends Paid | CN¥25.90 Million | -14.62% |
| Other Comprehensive Income | CN¥-42.23 Million | -23.83% |
| Other Changes | CN¥67.75 Million | +38.23% |
| Total Change | CN¥- | -36.56% |
Book Value vs Market Value Analysis
This analysis compares Jiangsu Nanfang Medical's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.63x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 13.57x to 12.63x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.57 | CN¥7.74 | x |
| 2013-12-31 | CN¥0.79 | CN¥7.74 | x |
| 2014-12-31 | CN¥0.98 | CN¥7.74 | x |
| 2015-12-31 | CN¥1.03 | CN¥7.74 | x |
| 2016-12-31 | CN¥1.18 | CN¥7.74 | x |
| 2017-12-31 | CN¥2.24 | CN¥7.74 | x |
| 2018-12-31 | CN¥1.93 | CN¥7.74 | x |
| 2019-12-31 | CN¥2.02 | CN¥7.74 | x |
| 2020-12-31 | CN¥2.43 | CN¥7.74 | x |
| 2021-12-31 | CN¥2.28 | CN¥7.74 | x |
| 2022-12-31 | CN¥2.10 | CN¥7.74 | x |
| 2023-12-31 | CN¥1.62 | CN¥7.74 | x |
| 2024-12-31 | CN¥0.95 | CN¥7.74 | x |
| 2025-12-31 | CN¥0.61 | CN¥7.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Jiangsu Nanfang Medical utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -57.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -16.94%
- • Asset Turnover: 0.65x
- • Equity Multiplier: 5.24x
- Recent ROE (-57.40%) is below the historical average (-0.05%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 29.47% | 8.42% | 1.12x | 3.13x | CN¥23.63 Million |
| 2013 | 28.50% | 9.41% | 1.37x | 2.21x | CN¥31.19 Million |
| 2014 | 25.48% | 11.36% | 1.08x | 2.09x | CN¥32.43 Million |
| 2015 | 23.20% | 11.83% | 0.91x | 2.14x | CN¥29.16 Million |
| 2016 | 20.55% | 11.70% | 0.86x | 2.04x | CN¥26.68 Million |
| 2017 | 8.95% | 9.74% | 0.59x | 1.55x | CN¥-5.58 Million |
| 2018 | 7.05% | 8.18% | 0.57x | 1.52x | CN¥-16.42 Million |
| 2019 | 4.97% | 5.71% | 0.57x | 1.54x | CN¥-28.36 Million |
| 2020 | 14.07% | 9.14% | 1.00x | 1.54x | CN¥28.39 Million |
| 2021 | -3.50% | -4.32% | 0.43x | 1.90x | CN¥-87.74 Million |
| 2022 | -2.38% | -2.69% | 0.37x | 2.36x | CN¥-76.31 Million |
| 2023 | -31.41% | -24.57% | 0.47x | 2.72x | CN¥-194.34 Million |
| 2024 | -68.27% | -31.64% | 0.57x | 3.78x | CN¥-218.60 Million |
| 2025 | -57.40% | -16.94% | 0.65x | 5.24x | CN¥-119.43 Million |
Industry Comparison
This section compares Jiangsu Nanfang Medical's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $1,111,929,915
- Average return on equity (ROE) among peers: 10.25%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Jiangsu Nanfang Medical (603880) | CN¥163.51 Million | 29.47% | 4.35x | $327.37 Million |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $1.81 Billion | 2.97% | 1.05x | $419.89 Million |
| Blue Sail Medical Co Ltd (002382) | $1.30 Billion | 13.93% | 0.22x | $831.57 Million |
| Andon Health Co Ltd (002432) | $758.75 Million | 1.34% | 0.32x | $3.56 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $1.02 Billion | 24.36% | 0.86x | $778.40 Million |
| Guangzhou Improve Med Instrument (300030) | $930.46 Million | 4.28% | 0.55x | $312.18 Million |
| QITIAN Technology Group Co Ltd (300061) | $408.78 Million | 0.00% | 0.59x | $729.02 Million |
| Shanghai Tofflon Science Tech (300171) | $3.12 Billion | 2.26% | 0.50x | $1.53 Billion |
| Truking Technology Ltd (300358) | $224.96 Million | 31.22% | 1.46x | $944.90 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $978.79 Million | 15.93% | 0.44x | $734.18 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $574.90 Million | 6.24% | 0.48x | $1.30 Billion |
About Jiangsu Nanfang Medical
Jiangsu Nanfang Medical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of transdermal products, medical adhesive tapes and bandages, sports protective equipment, first aid kits, nitrile gloves, and protective equipment in China and internationally. The company offers medical proof fabrics, care products, band-aids, and applications; medical w… Read more